NewLink Genetics Corp. (NASDAQ:NLNK) shares traded down 4.5% during mid-day trading on Wednesday . The stock traded as low as $11.15 and last traded at $11.20, with a volume of 205,443 shares. The stock had previously closed at $11.73.
Separately, Zacks Investment Research raised shares of NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Tuesday, July 5th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $23.29.
The company’s 50 day moving average is $10.45 and its 200 day moving average is $13.04. The stock’s market capitalization is $336.33 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/newlink-genetics-corp-nlnk-trading-down-4-5.html
NewLink Genetics Corp. (NASDAQ:NLNK) last issued its earnings results on Friday, July 29th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($0.77) by $0.35. NewLink Genetics Corp. had a negative return on equity of 51.33% and a negative net margin of 316.38%. Analysts expect that NewLink Genetics Corp. will post ($3.06) EPS for the current year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. American International Group Inc. increased its position in shares of NewLink Genetics Corp. by 1.4% in the second quarter. American International Group Inc. now owns 12,455 shares of the company’s stock valued at $140,000 after buying an additional 174 shares during the last quarter. Nationwide Fund Advisors increased its position in shares of NewLink Genetics Corp. by 5.8% in the second quarter. Nationwide Fund Advisors now owns 14,160 shares of the company’s stock valued at $159,000 after buying an additional 770 shares during the last quarter. BlackRock Group LTD increased its position in shares of NewLink Genetics Corp. by 35.0% in the first quarter. BlackRock Group LTD now owns 11,105 shares of the company’s stock valued at $203,000 after buying an additional 2,879 shares during the last quarter. Parametrica Management Ltd purchased a new position in shares of NewLink Genetics Corp. during the first quarter valued at approximately $216,000. Finally, SECOR Capital Advisors LP purchased a new position in shares of NewLink Genetics Corp. during the second quarter valued at approximately $224,000. 50.10% of the stock is currently owned by institutional investors.
About NewLink Genetics Corp.
NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.
Receive News & Ratings for NewLink Genetics Corp. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NewLink Genetics Corp. and related companies with MarketBeat.com’s FREE daily email newsletter.